232 related articles for article (PubMed ID: 35004669)
1. LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
Zheng X; Liao X; Nie L; Lin T; Xu H; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Cell Dev Biol; 2021; 9():748280. PubMed ID: 35004669
[No Abstract] [Full Text] [Related]
2. A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.
Zheng X; Zhou X; Xu H; Jin D; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Genet; 2021; 12():764184. PubMed ID: 34899849
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
[TBL] [Abstract][Full Text] [Related]
4. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
6. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
9. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
10. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
11. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
Front Oncol; 2020; 10():1429. PubMed ID: 32974156
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune-infiltrating cell-related biomarkers in hepatocellular carcinoma based on gene co-expression network analysis.
Hou Y; Zhang G
Diagn Pathol; 2021 Jul; 16(1):57. PubMed ID: 34218795
[TBL] [Abstract][Full Text] [Related]
13. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
14. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
[TBL] [Abstract][Full Text] [Related]
15. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.
Zheng Z; Mao S; Zhang W; Liu J; Li C; Wang R; Yao X
Front Oncol; 2020; 10():542492. PubMed ID: 33392066
[TBL] [Abstract][Full Text] [Related]
17. Malignant Tumor Purity Reveals the Driven and Prognostic Role of
Lu X; Li C; Xu W; Wu Y; Wang J; Chen S; Zhang H; Huang H; Huang H; Liu W
Front Oncol; 2021; 11():676124. PubMed ID: 34557404
[TBL] [Abstract][Full Text] [Related]
18. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
19. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
20. The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.
Gaffney SG; Perry EB; Chen PM; Greenstein A; Kaech SM; Townsend JP
Oncotarget; 2019 Jul; 10(44):4532-4545. PubMed ID: 31360302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
